SciClone agrees to add three Sigma-Tau nominees to board

By Lisa Kerner

Charlotte, N.C., March 31 - SciClone Pharmaceuticals, Inc. reached a settlement agreement that will give shareholder Sigma-Tau Finanziaria, SpA three seats on the company's board of directors, it was announced on Tuesday.

The three Sigma-Tau designees are Dr. Roberto Camerini, Trevor Jones and Gregg Lapointe. In December, Sigma-Tau named the three, plus one additional candidate, as its nominees.

Camerini is the head of clinical research II-worldwide drug development for Sigma-Tau.

Jones is an independent director of Sigma-Tau Finanziaria and a consultant to Sigma-Tau Pharmaceuticals.

Lapointe is the chief executive officer of Sigma-Tau Pharmaceuticals, which conducts Sigma-Tau's business in the United States.

SciClone said it added Jones to the board's compensation committee and the nominating and corporate governance committee. Lapointe was named to the business development committee, and Camerini was appointed to the newly formed scientific review committee.

The SciClone board will be reduced to eight members from 10, and current board members John Baxter and Rolf Henel will not stand for re-election.

Sigma-Tau agreed to vote its shares in favor of the election of the company's slate, which also includes SciClone president and CEO Dr. Friedhelm Blobel, Dean Woodman, Richard Hawkins, Ira Lawrence and Jon Saxe.

Under the settlement agreement, Sigma-Tau is prohibited from soliciting proxies, purchasing additional shares, forming groups with any third parties or taking certain other actions through Dec. 31.

SciClone is a Foster City, Calif.-based biopharmaceutical company.

Rome-based Sigma-Tau is SciClone's largest shareholder as well as its European development and marketing partner.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.